Disease Detection International
This article was originally published in The Gray Sheet
Executive Summary
Considering proposal by Irish firm Trinity Biotech to merge via a stock swap. DDI announced Jan. 17 that it had received a letter of intent from Trinity's board proposing a merger of the two companies. The proposal "contemplates an exchange of shares in which stockholders of Disease Detection International, other than Trinity, would receive American Depositary Receipts representing ordinary shares of Trinity," the release states. Trinity, which reportedly owns about 400,000 shares of DDI's common stock and all of the company's Series A preferred stock, holds a license to DDI's SeroCard diagnostic test for sexually transmitted and infectious diseases. Using the rapid test format of the SeroCard along with a saliva detection method obtained from Amsterdam-based Saliva Technologies, Trinity is developing a test to detect HIV-1 antibodies in saliva ("The Gray Sheet" April 26, 1993, I&W-4)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.